{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:06:00Z","timestamp":1762506360995},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1097\/mou.0000000000000064","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T14:21:22Z","timestamp":1400250082000},"page":"352-357","source":"Crossref","is-referenced-by-count":22,"title":["Biomarkers in lower urinary tract symptoms\/overactive bladder"],"prefix":"10.1097","volume":"24","author":[{"given":"Tiago","family":"Antunes-Lopes","sequence":"first","affiliation":[]},{"given":"C\u00e9lia D.","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Karl D.","family":"Sievert","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-6-20210206","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R2-6-20210206","first-page":"382431","article-title":"Biomarkers in overactive bladder: a new objective and noninvasive tool Adv U","volume":"2011","author":"Antunes-Lopes","year":"2011","journal-title":"rol"},{"key":"R3-6-20210206","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrurol.2011.7","article-title":"Novel biomarkers for overactive bladder.","volume":"8","author":"Cartwright","year":"2011","journal-title":"Nat Rev Urol"},{"key":"R4-6-20210206","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.ajog.2011.02.052","article-title":"The relationship between the Trp 64 Arg polymorphism of the beta 3-adrenoceptor gene and idiopathic overactive bladder.","volume":"205","author":"Ferreira","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R5-6-20210206","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1067\/mob.2002.125704","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.","volume":"187","author":"Abrams","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R6-6-20210206","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.eururo.2013.04.042","article-title":"Future direction in pharmacotherapy for nonneurogenic male lower urinary tract symptoms.","volume":"64","author":"Soler","year":"2013","journal-title":"Eur Urol"},{"key":"R7-6-20210206","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.eururo.2010.12.032","article-title":"Near-infrared spectroscopy: a novel, noninvasive, diagnostic method for detrusor overactivity in patients with overactive bladder symptoms - a preliminary and experimental study.","volume":"59","author":"Farag","year":"2011","journal-title":"Eur Urol"},{"key":"R8-6-20210206","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.urology.2012.05.036","article-title":"Use of near-infrared spectroscopy as an alternative to videourodynamics to detect detrusor overactivity in women with the overactive bladder syndrome.","volume":"80","author":"Mastoroudes","year":"2012","journal-title":"Urology"},{"key":"R9-6-20210206","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/nau.22222","article-title":"Can we identify men who will have complications from benign prostatic obstruction (BPO) ICI-RS.","volume":"31","author":"Oelke","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"R10-6-20210206","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1464-410X.2010.09367.x","article-title":"Transvaginal ultrasound measurement of bladder wall thickness: a more reliable approach than transperineal and transabdominal approaches.","volume":"106","author":"Panayi","year":"2010","journal-title":"BJU Int"},{"key":"R11-6-20210206","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1471-0528.1996.tb09910.x","article-title":"Ultrasound: a noninvasive screening test for detrusor instability.","volume":"103","author":"Khullar","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"key":"R12-6-20210206","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00192-010-1194-1","article-title":"Ultrasound measurement of bladder wall thickness in different forms of detrusor overactivity.","volume":"21","author":"Serati","year":"2010","journal-title":"Int Urogynecol J"},{"key":"R13-6-20210206","first-page":"325","article-title":"Sonographic transvaginal bladder wall thickness: does the measurement discriminate between urodynamic diagnoses Neurourol U","volume":"30","author":"Kuhn","year":"2011","journal-title":"rodyn"},{"key":"R14-6-20210206","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00404-013-3092-5","article-title":"Ultrasound assessment of bladder wall thickness as a screening test for detrusor instability.","volume":"289","author":"Abou-Gamrah","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"R15-6-20210206","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/nau.20741","article-title":"Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.","volume":"29","author":"Kuo","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"R16-6-20210206","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1464-410X.2009.08927.x","article-title":"Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder.","volume":"105","author":"Chung","year":"2010","journal-title":"BJU Int"},{"key":"R17-6-20210206","first-page":"841","article-title":"Is the beneficial effect of antimuscarinics related to motor or sensory changes in the bladder Int Urogynecol","volume":"21","author":"Panayi","year":"2010","journal-title":"J"},{"key":"R18-6-20210206","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1016\/S1569-9056(13)61263-4","article-title":"The effect of solifenacin on bladder wall thickness in women with overactive bladder syndrome and detrusor overactivity: results from the SHRINK study.","volume":"12","author":"Robinson","year":"2013","journal-title":"Eur Urol Suppl"},{"key":"R19-6-20210206","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nrurol.2012.178","article-title":"Neurotrophins as regulators of urinary bladder function.","volume":"9","author":"Ochodnicky","year":"2012","journal-title":"Nat Rev Urol"},{"key":"R20-6-20210206","first-page":"372","article-title":"Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB) BJU I","volume":"111","author":"Seth","year":"2013","journal-title":"nt"},{"key":"R21-6-20210206","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.juro.2012.08.187","article-title":"Urinary neurotrophic factors in healthy individuals and overactive bladder patients.","volume":"189","author":"Antunes-Lopes","year":"2013","journal-title":"J Urol"},{"key":"R22-6-20210206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11255-013-0540-x","article-title":"Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder.","volume":"46","author":"Wang","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"R24-6-20210206","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1464-410X.2009.08380.x","article-title":"Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.","volume":"103","author":"Liu","year":"2009","journal-title":"BJU Int"},{"key":"R25-6-20210206","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","article-title":"Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.","volume":"56","author":"Liu","year":"2009","journal-title":"Eur Urol"},{"key":"R26-6-20210206","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1464-410X.2008.07757.x","article-title":"Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women.","volume":"102","author":"Liu","year":"2008","journal-title":"BJU Int"},{"key":"R27-6-20210206","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1152\/physrev.00030.2012","article-title":"Urothelial signaling.","volume":"93","author":"Birder","year":"2013","journal-title":"Physiol Rev"},{"key":"R28-6-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11302-013-9395-y","article-title":"Purinergic signalling in the urinary tract in health and disease.","volume":"10","author":"Burnstock","year":"2014","journal-title":"Purinergic Signal"},{"key":"R29-6-20210206","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.eururo.2009.11.042","article-title":"In vitro release of adenosine triphosphate from the urothelium of human bladders with detrusor overactivity, both neurogenic and idiopathic.","volume":"57","author":"Kumar","year":"2010","journal-title":"Eur Urol"},{"key":"R31-6-20210206","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1152\/ajprenal.00291.2013","article-title":"Purinergic and muscarinic modulation of ATP release from the urothelium and its paracrine actions.","volume":"306","author":"Sui","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"R32-6-20210206","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/nau.22344","article-title":"Correlation between cystometric volumes, ATP release, and pH in women with overactive bladder versus controls.","volume":"32","author":"Cheng","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"R33-6-20210206","doi-asserted-by":"crossref","first-page":"e64696","DOI":"10.1371\/journal.pone.0064696","article-title":"Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.","volume":"8","author":"Silva-Ramos","year":"2013","journal-title":"PLoS One"},{"key":"R34-6-20210206","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2220\/biomedres.30.287","article-title":"Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder.","volume":"30","author":"Sugaya","year":"2009","journal-title":"Biomed Res"},{"key":"R35-6-20210206","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0022-5347(05)00992-4","article-title":"Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.","volume":"175","author":"Kim","year":"2006","journal-title":"J Urol"},{"key":"R36-6-20210206","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11255-009-9647-5","article-title":"Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study.","volume":"42","author":"Tyagi","year":"2010","journal-title":"Int Urol Nephrol"},{"key":"R37-6-20210206","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00192-011-1401-8","article-title":"Differential profile analysis of urinary cytokines in patients with overactive bladder.","volume":"22","author":"Ghoniem","year":"2011","journal-title":"Int Urogynecol J"},{"key":"R38-6-20210206","doi-asserted-by":"crossref","first-page":"e76706","DOI":"10.1371\/journal.pone.0076706","article-title":"Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"R39-6-20210206","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/nau.20938","article-title":"Elevation of serum c-reactive protein in patients with OAB and ICBPS implies chronic inflammation in the urinary bladder.","volume":"30","author":"Chung","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R40-6-20210206","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00192-012-1715-1","article-title":"The role of serum C-reactive protein in women with lower urinary tract symptoms.","volume":"23","author":"Hsiao","year":"2012","journal-title":"Int Urogynecol J"},{"key":"R41-6-20210206","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/nau.21118","article-title":"Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.","volume":"30","author":"Liu","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R42-6-20210206","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1464-410X.2009.08851.x","article-title":"Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitisbladder pain syndrome and detrusor overactivity.","volume":"106","author":"Liu","year":"2010","journal-title":"BJU Int"},{"key":"R43-6-20210206","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.juro.2013.08.082","article-title":"Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.","volume":"191","author":"Chapple","year":"2014","journal-title":"J Urol"},{"key":"R44-6-20210206","first-page":"191","article-title":"Is the bladder a reliable witness for predicting detrusor overactivity J U","volume":"175","author":"Hashim","year":"2006","journal-title":"rol"},{"key":"R45-6-20210206","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-410X.2009.08361.x","article-title":"Does urodynamic verification of overactive bladder determine treatment success Results from a randomized placebo- controlled study.","volume":"103","author":"Malone-Lee","year":"2009","journal-title":"BJU Int"},{"key":"R46-6-20210206","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1464-410X.2007.07258.x","article-title":"Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence.","volume":"101","author":"Groenendijk","year":"2008","journal-title":"BJU Int"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0000000000000064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T18:37:01Z","timestamp":1716748621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201407000-00006"}},"subtitle":["a critical overview"],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0000000000000064","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}